ACCESSWIRE
05 Aug 2022, 01:25 GMT+10
NEW YORK, NY / ACCESSWIRE / August 4, 2022 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA)
Class Period: May 28, 2021 - May 24, 2022
Lead Plaintiff Deadline: August 5, 2022
Verrica Pharmaceuticals, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) there were manufacturing deficiencies at the facility where Verrica's contract manufacturer produced a bulk solution for the Company's lead product candidate, VP-102; (2) these deficiencies were not remediated when Verrica resubmitted its New Drug Application for VP-12 for molluscum; (3) the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in VRCA: https://www.kleinstocklaw.com/pslra-1/verrica-pharmaceuticals-inc-loss-submission-form?id=30576&from=1
TG Therapeutics, Inc. (NASDAQ:TGTX)
Class Period: January 15, 2020 - May 31, 2022
Lead Plaintiff Deadline: September 16, 2022
The TGTX lawsuit alleges that throughout the class period, TG Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in TGTX: https://www.kleinstocklaw.com/pslra-1/tg-therapeutics-loss-submission-form?id=30576&from=1
17 Education & Technology Group Inc. (NASDAQ:YQ)
This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded 17EdTech securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with 17EdTech's December 2020 initial public offering.
Lead Plaintiff Deadline: September 19, 2022
Throughout the class period, 17 Education & Technology Group Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) 17EdTech's K-12 Academic AST Services would end less than a year after the Company's initial public offering; (2) as part of its ongoing regulatory efforts, Chinese authorities would imminently curtail and/or end 17EdTech's core business; and (3) as a result, defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Learn about your recoverable losses in YQ: https://www.kleinstocklaw.com/pslra-1/17-education-technology-group-inc-loss-submission-form?id=30576&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm
Get a daily dose of Atlanta Leader news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Atlanta Leader.
More InformationSOLOMON ISLANDS: In a move that opponents said is aimed at controlling and censoring the media, the government of the ...
WASHINGTON D.C.: In July, a Florida man was killed by exploding Takata airbag inflators, possibly becoming the 20th death in ...
Israel has launched an unprovoked war against the Palestinian resistance group Islamic Jihad. The Israeli army assassinated a high-ranking commander ...
ISLAMABAD, Pakistan - Pakistan categorically denied on Thursday that a U.S. drone strike in Kabul that killed al-Qaeda chief Ayman ...
EAST NUSA TENGGARA, Indonesia: Hundreds of Indonesian tourism workers went on strike this week to protest a sharp rise in ...
NASSAU, Bahamas: A team of explorers have announced that they have uncovered a treasure, including coins, gemstones and priceless jewels, ...
NEW YORK CITY, New York: Amazon announced this week that it had purchased robotic vacuum maker iRobot for approximately $1.7 ...
RICHMOND, Virginia: Dominion Energy Virginia has received state approval to build an enormous offshore wind farm off the coast of ...
SYDNEY, NSW, Australia - Stocks in Asia were mixed on Monday, but gains and losses were modest.There is concern the ...
CANBERRA, Australia: Australia's new government has announced plans to ban the development of a coal mine located near the Great ...
WASHINGTON D.C.: The U.S. Transportation Department said it could require airlines to offer passengers a refund if their flight schedules ...
LONDON, England: In 2023, America's Major League Baseball is set to return to London for the first time since 2019, ...